" class="no-js "lang="en-US"> Touchlight Creates DNA Manufacturing Facility in London
Tuesday, April 23, 2024

Touchlight Completes Expansion, Creating One of the World’s Largest DNA Manufacturing Facilities in London

Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River Thames, London.

The expanded state-of-the-art facility’s manufacturing capacity has tripled and is now capable of producing more than 8kg a year. This exceeds the current, but growing, global supply of plasmid DNA for genetic medicine. The new facility has 11 suites and includes two class B filling suites with class A filling cabinets, warehousing, together with a quality control laboratory capability and has already received a successful customer quality audit from a Big Pharma company.

Jonny Ohlson, Touchlight’s Executive Chair and Founder, said: “Touchlight has a long-held belief that scientists, like all creatives, function best in beautiful spaces. Whilst it may not, on the face of it, seem logical to site a GMP manufacturing facility in a waterworks that has been derelict for 70 years, the site has a large footprint of beautiful Victorian buildings which, now converted, provide a stunning and iconic facility that is an inspiring place to work. I am sure our Victorian predecessors would be proud that we have converted it into one of the largest capacity DNA manufacturing sites in the world today.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more